Danil Makarov
Danil Makarov
Associate Professor of Urology and Health Policy, NYU School of Medicine
Verified email at - Homepage
Cited by
Cited by
Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options
MG Sanda, JA Cadeddu, E Kirkby, RC Chen, T Crispino, J Fontanarosa, ...
The Journal of urology 199 (3), 683-690, 2018
Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases …
DV Makarov, BJ Trock, EB Humphreys, LA Mangold, PC Walsh, JI Epstein, ...
Urology 69 (6), 1095-1101, 2007
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial
LS Marks, NA Mazer, E Mostaghel, DL Hess, FJ Dorey, JI Epstein, ...
Jama 296 (19), 2351-2361, 2006
Biomarkers for prostate cancer
DV Makarov, S Loeb, RH Getzenberg, AW Partin
Annual review of medicine 60, 139-151, 2009
Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression
H Samaratunga, DV Makarov, JI Epstein
Urology 60 (2), 315-319, 2002
Immortal time bias: a frequently unrecognized threat to validity in the evaluation of postoperative radiotherapy
HS Park, CP Gross, DV Makarov, BY James
International Journal of Radiation Oncology* Biology* Physics 83 (5), 1365-1373, 2012
Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 3 and 3 4 independent of the number of involved cores?
DV Makarov, H Sanderson, AW Partin, JI Epstein
The Journal of urology 167 (6), 2440-2442, 2002
Surgical decompression is associated with decreased mortality in patients with sepsis and ureteral calculi
MS Borofsky, D Walter, O Shah, DS Goldfarb, AC Mues, DV Makarov
The Journal of urology 189 (3), 946-951, 2013
The association between diffusion of the surgical robot and radical prostatectomy rates
DV Makarov, JB Yu, RA Desai, DF Penson, CP Gross
Medical care, 333-339, 2011
The RoboConsultant: telementoring and remote presence in the operating room during minimally invasive urologic surgeries using a novel mobile robotic interface
R Agarwal, AW Levinson, M Allaf, DV Makarov, A Nason, LM Su
Urology 70 (5), 970-974, 2007
Five-year nationwide follow-up study of active surveillance for prostate cancer
S Loeb, Y Folkvaljon, DV Makarov, O Bratt, A Bill-Axelson, P Stattin
European urology 67 (2), 233-238, 2015
How active is active surveillance? Intensity of followup during active surveillance for prostate cancer in the United States
S Loeb, D Walter, C Curnyn, HT Gold, H Lepor, DV Makarov
The Journal of urology 196 (3), 721-726, 2016
The effect of ureteral stent placement on post-ureteroscopy complications: a meta-analysis
DV Makarov, BJ Trock, ME Allaf, BR Matlaga
Urology 71 (5), 796-800, 2008
Pro–prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer
DV Makarov, S Isharwal, LJ Sokoll, P Landis, C Marlow, JI Epstein, ...
Clinical cancer research 15 (23), 7316-7321, 2009
p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape
S Isharwal, MC Miller, C Marlow, DV Makarov, AW Partin, RW Veltri
The Prostate 68 (10), 1097-1104, 2008
The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy
DV Makarov, EB Humphreys, LA Mangold, MA Carducci, AW Partin, ...
The Journal of urology 179 (1), 156-162, 2008
Robotic surgery claims on United States hospital websites
LX Jin, AM Ibrahim, NA Newman, DV Makarov, PJ Pronovost, MA Makary
Journal for Healthcare Quality 33 (6), 48-52, 2011
The cost implications of prostate cancer screening in the Medicare population
X Ma, R Wang, JB Long, JS Ross, PR Soulos, JB Yu, DV Makarov, ...
Cancer 120 (1), 96-102, 2014
Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer
O Bratt, Y Folkvaljon, MH Eriksson, O Akre, S Carlsson, L Drevin, ...
European urology 68 (1), 53-58, 2015
Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion—“nadir+ 2”?
ME Nielsen, DV Makarov, E Humphreys, L Mangold, AW Partin, PC Walsh
Urology 72 (2), 389-393, 2008
The system can't perform the operation now. Try again later.
Articles 1–20